Kornimate/medical-research-clean huggingface dataset:
tavns reduces postoperative pain and complications in patients with gastric and intestinal tumors

Conditions: TaVNS; Gastrointestinal Tumor Surgery; Visual Analogue Scale; Complications

Summary: postoperative acute pain control in patients with gastrointestinal tumors is not satisfactory, and surgical complications including gastrointestinal dysfunction, gastrointestinal fistula, abdominal and gastrointestinal hemorrhage, peritonitis and abscess, are still important factors affecting surgical outcomes, postoperative recovery, hospital stay, and even perioperative mortality. the application of tavns during the perioperative period can enhance or preserve vagal nerve function, which may protect important organ functions through multiple pathways such as alleviating pain and inflammatory responses caused by surgical trauma, improving gastrointestinal function, enhancing cardiovascular regulation, reducing postoperative nausea and vomiting, and accelerating postoperative recovery, thereby reducing postoperative complications and mortality.

subjects who met the inclusion criteria were enrolled in the clinical trial and received 2 interventions at the following times: the day before surgery, and the afternoon of the 1st day postoperatively (15:00-17:00), a total of 2 times. the intervention implementers used vagus nerve stimulation equipment to place electrodes in the tragus area of the outer ear of the subjects in the experimental group (tavns group). the control group (sham stimulation group) was set to have a pulse width of 200 μs, a frequency of 1 hz, and an initial current of 10 ma, which was gradually increased to the pain tolerance threshold of the subject, capped at 50 ma，last for one hour. the vas scores before and after stimulation for 10 minutes were recorded. 2) ecg monitoring: both groups were monitored with a dynamic ecg monitor during the intervention period, starting 10 minutes before stimulation and ending 10 minutes after stimulation. the sdnn (standard deviation of nn intervals) of the sinus rhythm was measured before and after stimulation for 10 minutes. a uniform standard was used for anesthesia induction and maintenance during surgery, and all patients used the same patient-controlled intravenous analgesia (pcia) plan.

Eligibility criteria:
inclusion criteria: age 18-80 years, bmi 18-30 kg/m², asa ⅱ-ⅲ, elective laparoscopic gastric or intestinal tumor surgery, expected surgical duration ≥2 hours, patient understands study content and signs informed consent form. exclusion criteria: kidney replacement therapy, treatment for arrhythmias requiring treatment, dementia, severe bradycardia, orthostatic tachycardia syndrome, neuro-muscular disorders, auricular dermatitis, planned post-operative transfer to icu

Keywords: tavns perioperative period visual analogue scale complications
evaluation of the efficacy of omk2 in recovering corneal neural damage in patients with diabetes

Conditions: Cornea

Summary: this will be a single-centre, randomized, pilot study. 30 patients with diabetes who previously had received argon laser photocoagulation will be enrolled.

this will be a single-centre, randomized, pilot study. 30 patients with diabetes who previously had received argon laser photocoagulation will be enrolled. these patients will receive corneal esthesiometry and will be divided in those with esthesiometry \< 45 mm \[6\] (clinically detectable corneal neuropathy, cdcn) and not (ncdcn). patients will be randomized to the two treatment arms: 20 patients will be treated with active treatment (omk2) and 10 patients will be treated with placebo (lubricant eye drops) given three times daily (8 am, 2 pm, 8 pm) for 18 months. stratification for (1) cdcn, (2) duration of the disease, and (3) insulin-dependent diabetes will be adopted. the randomization will be operator-masked.

Eligibility criteria:
inclusion criteria: * at least 18 years old * type 1 or type 2 diabetic patients who received argon laser photocoagulation exclusion criteria: * neuropathy of any other cause than diabetes * a history of conditions known to affect corneal sensitivity * coexisting other corneal diseases * autoimmune diseases * sjogren syndrome * history of corneal trauma * contact lenses users * patients needing eye surgery or who received eye surgery at least 180 days before study beginning. * contraindications to the use of any active substances and/or excipients * pregnant and lactating women * pediatric patients or adolescents under 18 years

Keywords: cornea diabetes neural damage
optimization of 18f-fdg pet/ct response assessment and prognostic evaluation strategies for high-metabolism lymphoma

Conditions: Lymphoma

Summary: to develop a novel method for evaluating treatment response in lymphoma by utilizing pet/ct imaging data from patients with high-metabolic lymphoma. this involves comparing end-of-treatment pet (eot-pet) with interim pet (ipet) results to establish a new response assessment approach. the aim is to contrast this method with the lugano classification criteria, providing clinicians with more scientific and accurate tools for response evaluation and prognosis prediction.

this study adopted a multicenter retrospective cohort design. a total of 2,000 patients with highly metabolic lymphoma who underwent pet/ct scans and had clinical data available at ruijin hospital, affiliated with shanghai jiao tong university school of medicine, from june 2013 to december 2023, were selected for model development. the model was validated using an external validation cohort of 2,000 patients with highly metabolic lymphoma who underwent pet/ct scans at other institutions, including west china hospital of sichuan university. all patients were required to have undergone 18f-fdg pet/ct scans before treatment, during treatment, and after treatment. lesions were manually delineated, and software was used to automatically calculate pet/ct parameters such as suvmax, metabolic tumor volume (mtv), and total lesion glycolysis (tlg) for primary and metastatic lesions based on 18f-fdg pet/ct. clinical data for all patients were collected from their medical records, including age, gender, ldh levels, b symptoms, extranodal involvement, ipi score, presence of bulky disease, pathological subtype, and treatment regimen. each patient's end-of-treatment pet/ct was compared with baseline pet/ct based on the lugano criteria to evaluate treatment response, and the results were recorded in group a. correspondingly, the end-of-treatment pet/ct was also compared with interim pet/ct to derive a new treatment response evaluation, and the results were recorded in group b. the treatment response evaluations from groups a and b were then compared. statistical analysis was performed to identify patients with inconsistent treatment response evaluations between the two groups. additionally, it was recorded whether the treatment plan for each patient was altered at the end of first-line therapy based on the treatment response evaluation from group b.

Eligibility criteria:
inclusion criteria: 1. histopathologically confirmed high-metabolic lymphoma 2. underwent 18f-fdg pet/ct imaging before, during, and after treatment 3. treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations 4. complete clinicopathological and follow-up data available exclusion criteria 1: history of prior antitumor treatment 2: history of other malignancies 3: incomplete clinical data or imaging records 4: presence of other concurrent malignant tumors

Keywords: pet/ct lymphoma 18f-fdg
bring-up prevention

Conditions: Ischemic Heart Disease; Cerebrovascular Disorders; Peripheral Arterial Disease

Summary: the aim of this observational study is to assess in patients with a documented athero-thrombotic event: coronary artery disease (cad), cerebrovascular disease (cvd), peripheral artery disease (pad): * the level of adherence to guideline recommendations with the assumption to improve the rate of patients at goal for cholesterol levels. * the level of adherence to guideline recommendations and the rate of patients at goal for the other relevant and modifiable risk factors for cardiovascular event recurrence.

observational, prospective, multicenter study conducted in a large, representative sample of italian cardiology centers. phases: 1. first educational intervention to discuss the recommendations of guidelines for secondary prevention strategies. 2. data collection for 3 months or up to 30 consecutive patients in patients with documented cad/cvd/pad on a web case record form (crf) generating warning on the most relevant guideline recommendations, and, when guidelines are not followed, asking the reason for non-adherence. 3. evaluation of the primary and secondary end-points of the study at 6 months after enrollment. 4. second educational intervention to share the results of the first enrollment period of the study focusing the attention on existing gaps between guidelines recommendations and clinical practice. 5. new data collection for 3 months or up to 30 consecutive patients in patients with documented cad/cvd/pad on a web crf generating warning on the most relevant guideline recommendations, and, when guidelines are not followed, asking the reason for non-adherence. 6. additional evaluation of the primary and secondary end-points of the study at 6 months after enrollment. 7. 12-month follow-up for all patients included in both enrolment phases.

Eligibility criteria:
inclusion criteria: * both sexes at birth, age ≥18 years at least one of the following clinical conditions: * documented cad defined as: * prior acute coronary syndrom (acs) * prior coronary artery bypass graft (cabg) * prior percutaneous coronary intervention (pci) * documented pad (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease, ankle brachial index (abi)\<90). * documented cvd: ischemic stroke, previous carotid vascular interventions. * signed informed consent. exclusion criteria: * active neoplasia or very severe disease compromising short-medium term life expectancy. * participation in interventional studies. * patients already enrolled into the study from another participating center or in the previous enrolling phase.
phase ii study of whole or partial parotid sparing intensity modulated radiotherapy in patients with head and neck cancers

Conditions: Head and Neck Cancer

Summary: phase ii and iii studies have demonstrated imrt to be safe and standard practice for head and neck cancers treated with radiotherapy. this study will be an extension to an earlier, in-house, trial to allow continued recording of toxicities and outcomes in patients receiving imrt for head and neck cancers. this study will allow us to examine radiobiological modelling for normal tissue complication probability and in particular, determining the dose threshold for parotid glands. our primary objective is to assess the potential effectiveness of intensity-modulated radiotherapy (imrt) in reducing xerostomia in head and neck cancer patients and determining threshold dose for whole parotid gland and superficial lobes of parotid glands


Eligibility criteria:
inclusion criteria: * histologically confirmed squamous cell cancer or undifferentiated cancer of nasopharynx, oropharynx, larynx and hypopharynx and squamous cell carcinoma unknown primary. * tnm stage: t1-4, n0-3 m0 * patients requiring primary or postoperative radiotherapy to the primary site and bilateral neck irradiation requiring imrt * parotid sparing imrt feasible (parotids clear of malignant disease) * who performance status 0-1 (karnofsky \>80) * aged 18 or older * induction chemotherapy and concomitant platinum based chemotherapy is permitted * concomitant cetuximab is permitted where platinum chemotherapy is contraindicated * all patients must be suitable to attend regular follow-up and salivary flow measurements and be available for long term follow up. * all patients must be able to complete self-assessed quality of life questionnaire * be able to provide written informed consent exclusion criteria: * previous radiotherapy to the parotid gland/s * pre-existing salivary gland pathology interfering with saliva production * previous or concurrent illness which in the investigator's opinion which will interfere with either completion of therapy or follow up * brachytherapy is not allowed as part of the treatment * presence of lymphadenopathy adjacent to or involving both parotid glands making whole parotid sparing or superficial parotid sparing impossible * prophylactic use of amifostine or pilocarpine is not allowed
neurodynamics vs. stretching in soccer players with short hamstring syndrome

Conditions: Hamstring Contractures

Summary: comparison of the effects of passive stretching vs. sciatic nerve gliding in soccer players presenting with short hamstring syndrome.

soccer players from three teams in the region of murcia (spain) were recruited and randomly divided into three groups: control group, experimental group 1 and experimental group 2. in the control group passive shoulder mobilization will be applied, in experimental group 1 sciatic nerve gliding will be applied and in experimental group 2 passive hamstring stretching will be applied. treatments will be performed once a week for 4 weeks and measurements will be taken at week 1 and 4.

Eligibility criteria:
inclusion criteria: * soccer players of the murcia region federation who have short hamstring syndrome. * between 16 and 30 years of age. * to complete the informed consent form. exclusion criteria: * subjects with significant neurological pathology. * subjects with hamstring muscle injury. * subjects with lumbar pathology.

Keywords: peripheral nervous system muscle stretching exercises hamstring muscles sciatic nerve elasticity
the effectiveness of specialist seating provision for nursing home residents

Conditions: Physical Disability

Summary: a randomized control study aimed to investigate if suitable individualized seating provision is effective for adult nursing home residents in reducing the incidence of pressure ulcers, and increasing their quality of life and functioning.

the united kingdom (uk) population demographics confirm that older people are considered to be the fastest-growing group in the population (dunnell, 2008). in 2007, 9.8 million people were aged over 65; however, by 2032 this figure is projected to rise to 16.1 million (dunnell, 2008). many of these older adults will have complex health and social care needs sometimes requiring nursing home care. a high standard and quality of care within our nursing homes is essential, to be able to deal with this growing population safely and to the highest standard possible, including the provision of individualised seating assessment, prescription and provision. an individually prescribed seating system should be based upon the assessment of the person's abilities and needs, and should best position and support them for comfort and function. when seating is not clinically suitable for the user there are many physiological and psychological implications for the user. for example, often pressure ulcers may develop. pressure ulcers are currently a major concern for the nhs due to their prevalence, the cost of treatments and the impact on the person. pressure ulcers can often be related to poor seating and indeed good seating can contribute to prevention and contribute to healing (anton, 2005). current expenditure by the nhs in the uk on pressure sores is £2.1bn annually. this equates to approximately £10,500 per sore (bennett et al, 2004). anecdotal evidence suggests that correct seating provision could be instrumental in depleting this cost by preventing pressure ulcers through investment in chairs before ulcers develop. this project set out to explore this topic via empirical research methods. research question to identify the importance of individualised seating in reducing postural difficulties for adult residents in nursing homes. methods a pragmatic rct design with qualitative and quantitative tools was used. these included: pulse oximeter readings of oxygen saturation levels and pulse rate; braden scale of pressure risk; caregiver questionnaire; digital photographs of seated posture; and demographic information. participants forty residents were recruited from three nursing homes in n.ireland, and were randomly assigned to either the control group (continue to use existing chair) or the intervention group (use an individually configured seating system) for the 12- week trial period. at the end of the 12- week trial period there were 18 participants in each group.

Eligibility criteria:
inclusion criteria: * adult living in one of the three nursing home facilities exclusion criteria: * determined to be at a high risk of developing pressure ulcers (as per braden scale assessment)

Keywords: rct specialized seating pressure ulcers
adherence to oral antibiotics in patients with osteoarticular infections

Conditions: Bone and Joint Infection; Adherence, Medication

Summary: bone and joint infection (bji) are bacterial infections that can occur after surgery (nosocomial infections) or de novo. they constitute a public health problem in western countries . these infections are often difficult to treat, with a high rate of re-hospitalizations (19.5%) caused by relapses or recurrences. the treatment of bone and joint infection can be surgical and / or pharmacological . drug treatment is based on the use of parenteral and / or oral antibiotics. it is a curative therapy in most cases, with a prolonged duration ranging from 6 weeks to several months depending on the lesions . medication adherence, is a patients' behavior defined as drug intake with optimal attendance and regularity, as prescribed and explained by the physician. it is a key factor in the success of any drug therapy, as drugs don't work in patients who don't take them.. to the knowledge of investigators, there are no published data on the adherence to antibiotic therapy in patients treated for bone and joint infection. in addition to its prolonged duration, the antibiotic treatment of the osteoarticular infections may require several daily drug intakes and may be responsible for severe adverse effects, these three factors being known to adversely affect adherence. prevalence, adherence patterns over time and determinants of adherence in this patient population are not known. currently, drug adherence is not routinely evaluated and is not considered in the treatment of bone and joint infection in the regional center for complex bone and joint infection of the investigators. a specific study evaluating adherence to antibiotic therapy in patients treated for bone and joint infection appears to be justified.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * affiliation having a social security * diagnosis of bone and joint infections * surgical and clinical management of the infection at hospices civils de lyon * oral antibiotic therapy prescribed for a minimal duration of six weeks and a defined duration * patient's information given and informed consent obtained exclusion criteria: * oral antibiotic therapy for bone and joint infections with no defined duration (chronic therapy) * antibiotic therapy for bone and joint infections administered by parenteral route only * patient without a phone number or refusing to communicate by phone * patient with physical or mental disability impeding information and consent * patient with physical or mental disability impeding communication by phone
the perfusion use in stroke evaluation study

Conditions: Ischemic Stroke

Summary: this is an open label single center phase ii trial, evaluating the utility of 64 slice ct perfusion (ctp) in acute ischemic stroke (ais) patients. the main aim is to determine which aspects of ctp imaging can aid in expanding the time window for thrombolysis with iv (rt-pa) in ais patients up to 6 hours after symptom onset.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke * ≥ 18 years old * presentation up to 6 hours from time of onset of acute stroke symptoms exclusion criteria: * pregnancy * inability to receive ct scan * allergy to iv contrast * symptoms with full resolution * intracerebral hemorrhage * severe stroke which is classified as 'malignant' (hypodensity on noncontrast ct greater than 1/3 cerebral hemisphere) * premorbid mrs of \>3 * life expectancy of ≤3 months * any condition which, in the opinion of the investigator makes the subject unsuitable for study

Keywords: stroke tpa thrombolysis rt-pa ischemic ctp imaging ct perfusion imaging perfusion cta ct angiography acute ischemic stroke acute stroke therapy (ais)
a prospective patient reported outcomes and wearables study in myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasm

Summary: the investigators will assess the use of a smart phone app to monitor patient reported outcomes and record biometric data in patients with myeloproliferative neoplasms.

to determine whether the development of a dedicated myeloproliferative neoplasm (mpn) smartphone application is of benefit to mpn patients and shows utility for medical professionals to explore efficient disease management through retrieval of 'real-world' patient data. 1. to track symptoms and provide easy access to information: the core focus of the project is to enhance the quality of life for people with mpns. the app will serve as a comprehensive toolkit to help people with mpns proactively monitor and track their symptoms, leading to improved self-care. the app will also provide direct access to reliable, up-to-date information about mpns, empowering users to better understand their condition and make well-informed decisions regarding their health. 2. to contribute to research: the app will actively contribute to mpn research by generating valuable patient-generated real-world data to inform clinical trials, treatment development, and disease understanding. currently, most of the clinical information and data in this patient population comes from clinical trials and major academic centres. as such, there is a significant gap in recording practice and outcomes in other areas, which likely makes up a large proportion of the total patient population. the app would provide a means of monitoring patient experience, comorbidities, treatments, and outcomes, as well as highlighting unmet needs in this under-represented patient group. a 5-year sub-study using wearables is also planned to explore symptom management and collect biometric data to assess how this correlates with symptom burden, disease specific outcomes, treatment response and quality of life. the app's data collection capabilities have the potential to revolutionize the research landscape for mpns. by collecting large volume data from this patient group, researchers will be able to assess trends in treatment response, biomarker identification and allow optimisation of therapeutic pathways and improve design of clinical trials. this could lead to the development of new treatments being made more widely available to patients and potentially improve the lives of this patient population.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mpn. 2. resident in the uk 3. aged 18 years and over. 4. able to confidently converse in english language. 5. access to smartphone/ mobile phone. 6. capable of providing informed consent. 7. physically able to stand and ambulate independently (for substudy). exclusion criteria: * patients with a known allergic reaction to any materials in the wearable device (substudy). * patients who for any reason are not able to have a wearable (substudy). for example withings scanwatch should not be be used if the patient has an implantable electronic device such as a pacemaker or implantable cardioverter-defibrillator